Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2397)	8/3/2009 11:09:47 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MRNA has already closed its June 9 UG but not its June 10 DG <g> Today it is up about 10% on volume > 600Ks which is still below its ADV bigcharts.marketwatch.com It announced today positive data on its UsiRNA, demonstrating that they are highly potent against metabolic disease and cancer targets in rodent models. <g> The data showed that the knockdown of these targets is achieved via an RNAi-mediated process and is been presented . at the IBC Drug Discovery & Development Week, Oligonucleotide Therapeutics: From Concept to Implementation, in Boston. "Repeated positive results from multiple in vivo studies in rodents using our UsiRNAs and DiLA2 delivery platform has led us to the initiation of preclinical safety and efficacy studies in non-human primates," stated J. Michael French, President and Chief Executive Officer. "We are one of a handful of companies to have initiated non-human primate studies with a liposomal-based delivery system and we look forward to reporting positive data this quarter." It seems that with some good news the stock could get back to the $5 level.<g> bigcharts.marketwatch.com The spike on June 9 was when it announced that the FDA had approved its generic version of Miacalcin for nasal delivery. Back on April 2, it announced that it had sold its Manufacturing Business to Par Pharmaceuticals and it was concentrating on its RNAi projects. According to its CEO, Michael French, "that agreement eliminates all of MDRNA's non-RNAi expenses and represents the final step in our plan to create a company solely focused in the research and development of RNAi-based therapeutics." Bernard